

SCIENTIFIC PROGRAM
Pre- ACTRIMS/ECTRIMS joint virtual meeting
9-10 September 2020 - EDT time

A Continuing Medical Education Program Provided by



**European
Charcot
Foundation**



Pre- ACTRIMS/ECTRIMS joint virtual meeting

Overview

Increasing knowledge on the pathogenesis of multiple sclerosis (MS) has led to the development of new treatment strategies and novel prognostic biomarkers. Progressive MS, which has always been considered an "orphan" disease, is starting to be treated with disease modifying therapies; neuroprotective and remyelinating strategies are under investigation with the aim of promoting and preserving neuronal health. New measures suitable to establish the true effectiveness of these new therapeutic approaches are required and are currently tested in clinical trials. This course aims to provide updated scientific insights on the world of contemporary MS. International experts will address the main scientific breakthroughs in the field and will provide practical suggestions for managing patients in clinical practice.

Learning objectives

By attending this virtual meeting, you will be able to:

- Describe new pathogenetic mechanisms involved in MS and NMOS development
- Illustrate mechanisms of action and safety profile of new MS treatments
- Debate promising novel approaches to quantify MS activity

Target audience

This virtual meeting is designed for young neurologists and nurses with specific interest in MS.

Scientific Organizers

Giancarlo Comi

Director - Institute of Experimental Neurology (INSPE)
San Raffaele Scientific Institute - University Vita-Salute San Raffaele
Milan, Italy

Fred David Lublin

Saunders Family Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai - New York, USA

Language

The official language of this virtual meeting will be English.

Continuing medical education

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME®), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this live material for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through an agreement between the American Medical Association and the Union Européenne des Médecins Spécialistes, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.



JOINT ACCREDITATION™
INTERPROFESSIONAL CONTINUING EDUCATION



Registration

Registration is free of charge.

Please register on <https://academiccme.com/virtualms/>

Organizing Secretariat

For any information please contact:

AcademicCME

nbrestowski@academiccme.com
cbenedek@academiccme.com

EXCEMED Foundation

alessia.addressi@external.excedmed.org

Acknowledgement

This activity is supported by independent educational grants from Biogen, Janssen Neuroscience- Johnson&Johnson Company and Sanofi Genzyme.

AGENDA

EDT time

Wednesday, 9 September 2020	Virtual Module 1
8.00	How Genes and Environment Interact to Cause MS Alberto Ascherio, MD
8.20	NMOSD Kazuo Fujihara, MD
8.40	OCT and Neurofilaments in Clinical Practice Peter Calabresi, MD
9.00	Faculty Discussion Q & A
9.30	Standard MRI to Monitor Disease Courses and Treatment Response Douglas L. Arnold, MD
9.50	Advanced MRI to Monitor Disease Courses and Treatment Response Massimo Filippi, MD
10.10	The Spectrum of Treatments in RMS Giancarlo Comi, MD
10.30	Enhancing Remyelination: From Basic Studies to Interventions Hans-Peter Hartung, MD, PhD
10.50	New Perspectives in Neurorehabilitation Letizia Leocani, MD, PhD
11.10	Faculty Discussion Q & A and Conclusion
11.30	End of the Virtual Module 1

Thursday, 10 September 2020	Virtual Module 2
8.00	Understanding Progressive MS Fred D. Lublin, MD
8.20	Treatment Decisions in PMS Per Soelberg Sorensen, MD
8.40	Neuroprotective Treatments Giancarlo Comi, MD
9.00	Faculty Discussion Q & A
9.30	Are We Any Closer to Understanding the Cause of MS? Peter Calabresi, MD
9.50	Electronic Data Capture/Devices - Can We Quantitate Disease Activity? Jeffrey Cohen, MD
10.10	Is it Time to Consider Combination/Add-On Therapies? Fred D. Lublin, MD
10.30	Are We Paying Enough Attention to Safety? Hans-Peter Hartung, MD, PhD
10.50	Faculty Discussion Q & A and Conclusion
11.30	End of the Virtual Meeting